These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 35703651)
1. Cost-Effectiveness of Using the Coronary Artery Calcium Score in Guiding Therapeutic Decisions in Primary Prevention in the Brazilian Population. Valério RS; Generoso G; Fernandes JL; Nasir K; Hong JC; Bittencourt MS Arq Bras Cardiol; 2022; 118(6):1126-1131. PubMed ID: 35703651 [TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals. van Kempen BJ; Spronk S; Koller MT; Elias-Smale SE; Fleischmann KE; Ikram MA; Krestin GP; Hofman A; Witteman JC; Hunink MG J Am Coll Cardiol; 2011 Oct; 58(16):1690-701. PubMed ID: 21982314 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Using the Coronary Calcium Score to Guide Therapeutic Decisions in Primary Prevention in the Brazilian Population. Gottlieb I Arq Bras Cardiol; 2022 Jun; 118(6):1132-1133. PubMed ID: 35703652 [No Abstract] [Full Text] [Related]
4. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-Effectiveness Analysis. Hong JC; Blankstein R; Shaw LJ; Padula WV; Arrieta A; Fialkow JA; Blumenthal RS; Blaha MJ; Krumholz HM; Nasir K JACC Cardiovasc Imaging; 2017 Aug; 10(8):938-952. PubMed ID: 28797417 [TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Coronary Artery Calcium Scoring in People With a Family History of Coronary Disease. Venkataraman P; Kawakami H; Huynh Q; Mitchell G; Nicholls SJ; Stanton T; Tonkin A; Watts GF; Marwick TH; JACC Cardiovasc Imaging; 2021 Jun; 14(6):1206-1217. PubMed ID: 33454262 [TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113 [TBL] [Abstract][Full Text] [Related]
7. Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility Trial. Muhlestein JB; Knowlton KU; Le VT; Lappe DL; May HT; Min DB; Johnson KM; Cripps ST; Schwab LH; Braun SB; Bair TL; Anderson JL JACC Cardiovasc Imaging; 2022 May; 15(5):843-855. PubMed ID: 34922872 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective. Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ; Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756 [TBL] [Abstract][Full Text] [Related]
9. Cost utility of fractional flow reserve-guided percutaneous coronary intervention in multivessel coronary artery disease in Brazil. Stella SF; Polanczyk CA; Arvandi M; Siebert U Int J Qual Health Care; 2019 Nov; 31(9):676-681. PubMed ID: 30576452 [TBL] [Abstract][Full Text] [Related]
10. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Blake GJ; Ridker PM; Kuntz KM Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial. Cohen DJ; Osnabrugge RL; Magnuson EA; Wang K; Li H; Chinnakondepalli K; Pinto D; Abdallah MS; Vilain KA; Morice MC; Dawkins KD; Kappetein AP; Mohr FW; Serruys PW; Circulation; 2014 Sep; 130(14):1146-57. PubMed ID: 25085960 [TBL] [Abstract][Full Text] [Related]
12. Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease. Kohli-Lynch CN; Lewsey J; Boyd KA; French DD; Jordan N; Moran AE; Sattar N; Preiss D; Briggs AH Circulation; 2022 Apr; 145(17):1312-1323. PubMed ID: 35249370 [TBL] [Abstract][Full Text] [Related]
13. Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--Effectiveness Modeling Study. Galper BZ; Wang YC; Einstein AJ PLoS One; 2015; 10(9):e0138092. PubMed ID: 26422204 [TBL] [Abstract][Full Text] [Related]
14. Comparing the cost-effectiveness of four novel risk markers for screening asymptomatic individuals to prevent cardiovascular disease (CVD) in the US population. van Kempen BJ; Ferket BS; Steyerberg EW; Max W; Myriam Hunink MG; Fleischmann KE Int J Cardiol; 2016 Jan; 203():422-31. PubMed ID: 26547049 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness Analysis of Anatomic vs Functional Index Testing in Patients With Low-Risk Stable Chest Pain. Karády J; Mayrhofer T; Ivanov A; Foldyna B; Lu MT; Ferencik M; Pursnani A; Salerno M; Udelson JE; Mark DB; Douglas PS; Hoffmann U JAMA Netw Open; 2020 Dec; 3(12):e2028312. PubMed ID: 33315111 [TBL] [Abstract][Full Text] [Related]
16. Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness. Hageman SHJ; Dorresteijn JAN; Bots ML; Asselbergs FW; Westerink J; van der Meulen MP; Mosterd A; Visseren FLJ; ; Asselbergs FW; Nathoe HM; de Borst GJ; Bots ML; Geerlings MI; Emmelot MH; de Jong PA; Leiner T; Lely AT; van der Kaaij NP; Kappelle LJ; Ruigrok YM; Verhaar MC; Visseren FLJ; Westerink J Eur J Prev Cardiol; 2022 Mar; 29(4):635-644. PubMed ID: 34009323 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review. Gholami SS; Azar FEF; Rezapour A; Tajdini M Heart Fail Rev; 2019 Nov; 24(6):967-975. PubMed ID: 31179517 [TBL] [Abstract][Full Text] [Related]
18. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487 [TBL] [Abstract][Full Text] [Related]
19. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions. Kang HY; Ko SK; Liew D Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032 [TBL] [Abstract][Full Text] [Related]
20. Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery. Henriksson M; Palmer S; Chen R; Damant J; Fitzpatrick NK; Abrams K; Hingorani AD; Stenestrand U; Janzon M; Feder G; Keogh B; Shipley MJ; Kaski JC; Timmis A; Sculpher M; Hemingway H BMJ; 2010 Jan; 340():b5606. PubMed ID: 20085988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]